Observational Study in Patients Treated With JAK Inhibitors for Inflammatory Rheumatism (MAJIK)

Launched by SOCIETE FRANCAISE DE RHUMATOLOGIE · Oct 20, 2020

Keywords

ClinConnect Summary

The MAJIK trial is a national study focused on understanding the safety and effectiveness of a new type of medication called JAK inhibitors, which are used to treat chronic inflammatory rheumatic diseases like rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis. Researchers aim to enroll at least 1,500 patients with rheumatoid arthritis and 150 with psoriatic arthritis. They will follow these patients for five years to see how well the treatment works in everyday settings, helping doctors optimize its use in personalized medicine.

To participate in the study, you need to be an adult over 18 years old and currently receiving treatment with a JAK inhibitor for your condition. All participants will need to provide written consent to join. Throughout the study, you can expect regular check-ups and assessments to monitor your health and how the medication is working for you. This research is important because it will provide valuable information about how JAK inhibitors perform in real-life situations, which can benefit future patients and improve treatment strategies.

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • Patients older than 18
• • Patient treated with a JAK inhibitor in accordance with EMA, for chronic inflammatory rheumatisms, independent of the therapeutic line
• • Subject who is a member of a social security regime
• • Free, declared, written consent signed by the subject and the investigator on the day of inclusion Exclusion criteria
• • Patient who cannot understand the implications and rules of the study
• • Patient opposition to participating in the study